In the present study, we found that the less selective SGLT2 inhibitors were linked to a notably reduced risk of MACEs and exhibited more promising cardioprotective effects than highly selective SGLT2 inhibitors in the patients with HF. This evidence concerns the gene SLC5A2 and hydrops fetalis.